Profile data is unavailable for this security.
About the company
ABNOVA (TAIWAN) CORPORATION is a Taiwan-based company principally engaged in the manufacturing and sales of antibodies and proteins. The Company's products mainly include monoclonal antibodies, polyclonal antibodies, protein fragments, full-length proteins, active proteins, antibody pairs, fluorescence in situ hybridization probe and others. The Company's monoclonal and polyclonal antibodies are primarily applied in medical testing reagents, agricultural testing, industrial purification, medical treatment and other fields. Its proteins are mainly applied in medical testing reagents, agricultural testing, medical treatment, protein engineering and other fields. Its products are mainly traded in Taiwan, Americas and Europe.
- Revenue in TWD (TTM)371.63m
- Net income in TWD59.69m
- Incorporated2002
- Employees190.00
- LocationAbnova Taiwan Corp9F, No.108, Jhouzih StreetXi Hu Li, Neihu DistrictTAIPEI 114TaiwanTWN
- Phone+886 287511888
- Fax+886 287511166
- Websitehttps://www.abnova.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Applied BioCode Corp | 395.17m | -164.20m | 1.72bn | -- | -- | 2.60 | -- | 4.36 | -2.01 | -2.01 | 4.83 | 8.08 | 0.3583 | 0.8978 | 6.49 | -- | -14.89 | -18.20 | -16.29 | -19.88 | 68.01 | 62.21 | -41.55 | -59.48 | 6.52 | -- | 0.0495 | -- | 1.25 | 60.67 | 11.12 | -- | -19.25 | -- |
| Abnova Taiwan Corp | 371.63m | 59.69m | 1.93bn | 190.00 | 32.39 | 1.52 | 21.19 | 5.20 | 0.9849 | 0.9849 | 6.13 | 21.02 | 0.2694 | 0.4978 | 8.67 | -- | 4.33 | 2.85 | 4.69 | 3.01 | 45.73 | 45.92 | 16.06 | 8.82 | 5.23 | -- | 0.0057 | 86.93 | -7.21 | -2.16 | -41.64 | -1.08 | -10.00 | 3.71 |
| GenMont Biotech Inc | 354.81m | 59.50m | 2.09bn | 147.00 | 35.23 | 1.59 | 18.01 | 5.90 | 0.6869 | 0.6869 | 4.10 | 15.25 | 0.2076 | 1.52 | 11.06 | -- | 2.87 | 3.61 | 3.58 | 4.23 | 66.81 | 67.88 | 13.85 | 16.63 | 2.31 | -- | 0.0649 | 102.76 | -13.71 | -4.79 | -42.10 | -19.65 | -30.61 | -19.73 |
| Holder | Shares | % Held |
|---|---|---|
| Dimensional Fund Advisors LPas of 09 May 2024 | 248.00k | 0.41% |
| Polunin Capital Partners Ltd.as of 30 Jun 2023 | 66.19k | 0.11% |
| DFA Australia Ltd.as of 31 Dec 2023 | 1.09k | 0.00% |
